Evidence map›Paper›PMID 17206489›Full record

ArticleTransgenic research2007

Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice.

Sarah A Davie, Jeannie E Maglione, Cathyryne K Manner, Dmitri Young, Robert D Cardiff, Carol L MacLeod, Lesley G Ellies

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Transgenic research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 157 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. CXCR4Nature communications · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Elucidating Sex-Specific Immune Profiles in a Breast Cancer Model.International journal of molecular sciences · 2024
    Article
  15. Leveraging preclinical models of metastatic breast cancer.Biochimica et biophysica acta. Reviews on cancer · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sarah A DavieMoores UCSD Cancer Center, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA 92093-0063, USA.
Jeannie E Maglione
Cathyryne K Manner
Dmitri Young
Robert D Cardiff
Carol L MacLeod
Lesley G Ellies
University of California, San Diego · USUniversity of California, Davis · US

Funding

THE L-ARGININE: NO PATHWAY IN MAMMARY TUMOR PROGRESSIONR01CA081376 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI MACLEOD, CAROL L. · 2000 to 2003
$1.4M
ADHESION MOLECULES IN NO MODULATED TUMORIGENESISK08CA088035 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI ELLIES, LESLEY G · 2000 to 2004
$588k
NCI NIH HHS K08 CA088035NCI NIH HHS K08-CA88035NCI NIH HHS R01-CA81376
6 · The paper itself

Abstract

The ability to genetically manipulate mice has led to rapid progress in our understanding of the roles of different gene products in human disease. Transgenic mice have often been created in the FVB/NJ (FVB) strain due to its high fecundity, while gene-targeted mice have been developed in the 129/SvJ-C57Bl/6J strains due to the capacity of 129/SvJ embryonic stem cells to facilitate germline transmission. Gene-targeted mice are commonly backcrossed into the C57Bl/6J (B6) background for comparison with existing data. Genetic modifiers have been shown to modulate mammary tumor latency in mouse models of breast cancer and it is commonly known that the FVB strain is susceptible to mammary tumors while the B6 strain is more resistant. Since gene-targeted mice in the B6 background are frequently bred into the polyomavirus middle T (PyMT) mouse model of breast cancer in the FVB strain, we have sought to understand the impact of the different genetic backgrounds on the resulting phenotype. We bred mice deficient in the inducible nitric oxide synthase (iNOS) until they were congenic in the PyMT model in the FVB and B6 strains. Our results reveal that the large difference in mean tumor latencies in the two backgrounds of 53 and 92 days respectively affect the ability to discern smaller differences in latency due to the Nos2 genetic mutation. Furthermore, the longer latency in the B6 strain enables a more detailed analysis of tumor formation indicating that individual tumor development is not stoichastic, but is initiated in the #1 glands and proceeds in early and late phases. NO production affects tumors that develop early suggesting an association of iNOS-induced NO with a more aggressive tumor phenotype, consistent with human clinical data positively correlating iNOS expression with breast cancer progression. An examination of lung metastases, which are significantly reduced in PyMT/iNOS-/- mice compared with PyMT/iNOS+/+ mice only in the B6 background, is concordant with these findings. Our data suggest that PyMT in the B6 background provides a useful model for the study of inflammation-induced breast cancer.

Indexed as

PhenotypeAnimalsMammary Neoplasms, ExperimentalMiceMice, Inbred C57BLMice, KnockoutNitric Oxide Synthase Type IINitric Oxide Synthase Type II

Identifiers

PMID17206489
PMCPMC1829418
OpenAlexW2142226776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.